From a paper published in April this year…
Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
Recently, we reviewed how Rho/ROCK signaling pathway modulates acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), and indicated that by using specific Rho kinase inhibitors, we can prevent/treat such conditions. Activation of RhoA GTPase and its downstream effector, Rho kinase (ROCK), contributes to a burst in inflammatory features, immune cell migration, apoptosis, coagulation, contraction, and cell adhesion in pulmonary endothelial cells, leading to endothelium barrier dysfunction and edema as hallmarks of lung injury. Importantly, Rho kinase inhibitors …could significantly attenuate lung injury in different in vivo and in vitro models of ALI. Furthermore, excellent anti-fibrotic effects of Rho kinase inhibitors were shown in models of pulmonary fibrosis….Rho kinase inhibitors can suppress pathways involved in lung tissue destruction. So, we assume that clinical trials on the effects of Rho kinase inhibitors against respiratory complications induced by SARS-CoV-2 infection, should be conducted.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195000/
The authors note that RhoA GTPase contributes to the hallmarks of lung injury in acute lung injury and acute respiratory distress syndrome and that use of Rho kinase inhibitors can suppress pathways involved in lung tissue destruction. They conclude that clinical trials should be conducted on the effects of Rho kinase inhibitors against respiratory complications induced by COVID-19.
Prescient has stated that it believes that PTX-100 is the only RhoA inhibitor in the world in clinical development.
- Forums
- ASX - By Stock
- PTX
- Ann: 2 PTX Assets Chosen in Doherty Institute COVID-19 Program
Ann: 2 PTX Assets Chosen in Doherty Institute COVID-19 Program, page-54
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.04M |
Open | High | Low | Value | Volume |
4.8¢ | 4.8¢ | 4.5¢ | $98.21K | 2.157M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 472315 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.6¢ | 868129 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 472315 | 0.045 |
8 | 537386 | 0.044 |
6 | 241671 | 0.043 |
3 | 304000 | 0.042 |
1 | 250000 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.046 | 868129 | 2 |
0.048 | 660000 | 2 |
0.050 | 100000 | 1 |
0.051 | 44400 | 1 |
0.052 | 88389 | 1 |
Last trade - 15.51pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
4.5¢ |
  |
Change
0.000 ( 6.05 %) |
|||
Open | High | Low | Volume | ||
4.7¢ | 4.7¢ | 4.5¢ | 1078953 | ||
Last updated 15.39pm 06/05/2024 ? |
Featured News
PTX (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online